Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab combinations versus pembrolizumab monotherapy in first-line PD-L1-high advanced NSCLC
NL-OMON46388Phase 3Suspended
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jul 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cemiplimab, ipilimumab and pembrolizumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Progression-free survival. Started Jul 2018; status: suspended.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON46388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46388.